Main Menu
ASCO 2018 meeting logo

ICR presentations at ASCO 2018

The ICR will have many of our researchers present at the 2018 ASCO annual meeting taking place in Chicago from Friday 1 June. The theme of this year's conference is Delivering Discoveries: Expanding the Reach of Precision Medicine

This page provides links to the abstracts from all presentations involving ICR scientists. All abstracts can be searched on the ASCO meeting library website. 

Use abstract links to see more details. When senior ICR researchers are listed as the first author, a link to their ICR webpage is also provided. We have also provided a more comprehensive look at the conference in this blog post.

ASCO 2018 News — A major clinical trial has become the first to show benefits of immunotherapy in prostate cancer – for some men with advanced, otherwise untreatable disease. 

Read more

    Oral presentations

    • KEYNOTE: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)  —  Professor Johann de Bono — abstract link
    • Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer  (mCRPC) — abstract link
    • Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute — abstract link
    • Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC) — abstract link

    Poster presentations

    • Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) — Professor Kevin Harrington — abstract link
    • A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours  — Professor Udai Banerji — abstract link
    • Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232) —  Professor Kevin Harrington — abstract link
    • Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study) — Professor Winette van der Graaf — abstract link
    • Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer — abstract link
    • VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021) — abstract link
    • Independent prognostic value of the EORTC QLQ-C30 summary score on all-cause mortality: Results from the population-based PROFILES registry — abstract link
    • Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors — abstract link
    • The prognostic and predictive value of AR-V7 quantification in mCRPC — abstract link
    • Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer — abstract link
    •  Early changes in PSA and association with outcomes in mCRPC patients — abstract link
    • Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer — abstract link